PsychonautWiki Archive

Selective serotonin reuptake inhibitor: Difference between revisions

← Older editNewer edit →
>AstronautLizard
Section on escitalopram.
>Aleksandar8239
edited subjective effects
Line 16: Line 16:
{{effects/base
{{effects/base
|{{effects/physical|
|{{effects/physical|
*'''[[Effect::Sedation]]''' ''or'' '''[[Effect::stimulation]]''' - Most SSRIs are sedating while others can be mildly stimulating. The sedation produced by SSRIs is usually very mild during the day, but very intense at night. This can make one unable to stay awake at night, however is usually considered a positive effect by most people, as depression often is accompanied by insomnia.
*'''[[Effect::Sedation]]''' ''or'' '''[[Effect::stimulation]]''' - Some SSRIs are sedating (paroxetine and fluvoxamine), whereas some are mildly stimulating (sertraline and fluoxetine).
*'''[[Effect::Physical fatigue]]'''
*'''[[Effect::Physical fatigue]]'''
*'''[[Effect::Appetite enhancement]]''' ''or'' '''[[Effect::appetite suppression]]'''
*'''[[Effect::Appetite enhancement]]''' ''or'' '''[[Effect::appetite suppression]]'''
*'''[[Effect::Decreased libido]]''' - Very common. Could persist as PSSD after discontinuation.<ref>{{cite web|author=Pharmacovigilance Risk Assessment Committee (PRAC)|date=11 June 2019|title=New product information wording – Extracts from PRAC recommendations on signals|url=https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_en.pdf#page=2|publisher=European Medicines Agency|id=EMA/PRAC/265221/2019}}</ref> On the other hand, suppression of depression may enhance libido.
*'''[[Effect::Decreased libido]]''' - Very common. Could persist as PSSD after discontinuation.<ref>{{cite web|author=Pharmacovigilance Risk Assessment Committee (PRAC)|date=11 June 2019|title=New product information wording – Extracts from PRAC recommendations on signals|url=https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_en.pdf#page=2|publisher=European Medicines Agency|id=EMA/PRAC/265221/2019}}</ref>
*'''[[Effect::Orgasm suppression]]''' - This effect is usually mild and only delays orgasms, however in some people, particularly older users, SSRIs can make one completely unable to reach orgasm. This is usually treated by either switching to a different antidepressant, or adding a DNRI such as [[bupropion]]. Short-acting SSRIs such as dapoxetine are approved drugs for premature ejaculation.
*'''[[Effect::Orgasm suppression]]''' - This effect is dose-dependent and causes delayed orgasm, but in some people, especially older users, SSRIs can make one completely unable to reach orgasm. This is usually treated by either switching to a different antidepressant, or adding a NDRI such as [[bupropion]]. Short-acting SSRIs such as dapoxetine are approved drugs for premature ejaculation.
*'''[[Effect::Pain relief]]''' - Some studies suggest they can be effective as analgesics (painkillers).<ref>https://www.med.unc.edu/ibs/files/2017/10/IBS-and-Antidepressants.pdf</ref>
*'''[[Effect::Pain relief]]''' - Some studies suggest they can be effective as analgesics (painkillers).<ref>https://www.med.unc.edu/ibs/files/2017/10/IBS-and-Antidepressants.pdf</ref>
*'''[[Effect::Nausea]]''' - Nausea is mild and is usually only present upon first introduction and usually subsides after 6-8 weeks.
*'''[[Effect::Headaches]]''' - Headaches are usually only present upon first introduction and usually subside after 6-8 weeks.
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Increased perspiration]]'''
Line 33: Line 31:
SSRIs are capable of inconsistently inducing changes in visual perception - often during the beginning of treatment.  
SSRIs are capable of inconsistently inducing changes in visual perception - often during the beginning of treatment.  


Most effects often disappear after a few weeks of treatment but may reappear or become more prominent when combined with [[cannabis]] or [[amphetamines]].
Most effects disappear after a few weeks of treatment but may reappear or become more prominent when combined with [[cannabis]] or [[amphetamines]].


====Enhancements====
====Enhancements====
Line 40: Line 38:


====Distortions====
====Distortions====
*'''[[Effect::Tracers]]'''
*'''[[Effect::Visual drifting|Drifting]]''' ''([[Visual drifting#Melting|melting]], [[Visual drifting#Breathing|breathing]], [[Visual drifting#Morphing|morphing]] and [[Visual drifting#Flowing|flowing]])'' - This effect is most similar in presentation to the same effect from [[amphetamines]] but with a cartoony quality most reminiscent of psychedelics such as [[4-HO-MET]] and [[2C-B]]
*'''[[Effect::Visual drifting|Drifting]]''' ''([[Visual drifting#Melting|melting]], [[Visual drifting#Breathing|breathing]], [[Visual drifting#Morphing|morphing]] and [[Visual drifting#Flowing|flowing]])'' - This effect is most similar in presentation to the same effect from [[amphetamines]] but with a cartoony quality most reminiscent of psychedelics such as [[4-HO-MET]] and [[2C-B]]


Line 46: Line 45:
}}
}}
{{effects/cognitive|
{{effects/cognitive|
*'''[[Effect::Amotivational syndrome]]'''<ref>{{cite journal |last1=Barnhart |first1=WJ |last2=Makela |first2=EH |last3=Latocha |first3=MJ |title=SSRI-induced apathy syndrome: a clinical review. |journal=Journal of psychiatric practice |date=May 2004 |volume=10 |issue=3 |pages=196-9 |doi=10.1097/00131746-200405000-00010 |pmid=15330228}}</ref>
*'''[[Effect::Motivation suppression]]'''<ref>{{cite journal |last1=Barnhart |first1=WJ |last2=Makela |first2=EH |last3=Latocha |first3=MJ |title=SSRI-induced apathy syndrome: a clinical review. |journal=Journal of psychiatric practice |date=May 2004 |volume=10 |issue=3 |pages=196-9 |doi=10.1097/00131746-200405000-00010 |pmid=15330228}}</ref>
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Cognitive fatigue]]'''
*'''[[Effect::Cognitive fatigue]]'''
Line 53: Line 52:
*'''[[Effect::Ego inflation]]'''
*'''[[Effect::Ego inflation]]'''
*'''[[Effect::Emotion suppression]]''' - This effect is similar to but less intense compared to the [[emotion suppression]] induced by antipsychotics.
*'''[[Effect::Emotion suppression]]''' - This effect is similar to but less intense compared to the [[emotion suppression]] induced by antipsychotics.
*'''[[Effect::Emotion enhancement]]''' - Upon first introduction, some users can experience amplified emotions.
*'''[[Effect::Mania]]'''
*'''[[Effect::Mania]]'''
}}
}}
{{effects/paradoxical|
{{effects/paradoxical|
These effects are most often experienced upon first introduction.
These effects are most often experienced upon first introduction and usually subside after 6-8 weeks.
*'''[[Effect::Nausea]]'''
*'''[[Effect::Headache]]'''
*'''[[Effect::Depression]]'''
*'''[[Effect::Depression]]'''
*'''[[Effect::Anxiety]]'''
*'''[[Effect::Anxiety]]'''
*'''[[Effect::Emotion enhancement]]'''
*'''[[Effect::Thought disorganization]]'''
*'''[[Effect::Thought disorganization]]'''
*'''[[Effect::Irritability]]'''
*'''[[Effect::Irritability]]'''
*'''[[Effect::Motivation suppression]]'''
*'''[[Effect::Suicidal ideation]]'''<ref>{{cite journal | vauthors=((Björkenstam, C.)), ((Möller, J.)), ((Ringbäck, G.)), ((Salmi, P.)), ((Hallqvist, J.)), ((Ljung, R.)) | journal=PLoS ONE | title=An Association between Initiation of Selective Serotonin Reuptake Inhibitors and Suicide - A Nationwide Register-Based Case-Crossover Study | volume=8 | issue=9 | pages=e73973 | date=9 September 2013 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3767591/ | issn=1932-6203 | doi=10.1371/journal.pone.0073973}}</ref> - Upon first introduction, some users (especially people under the age of 25)<ref>{{Citation | title=What to know about antidepressants for kids and teens | url=https://www.mayoclinic.org/diseases-conditions/teen-depression/in-depth/antidepressants/art-20047502}}</ref> can experience increase suicidal and self harming thoughts and behaviors. This effect usually subsides within 6-8 weeks.
*'''[[Effect::Suicidal ideation]]'''<ref>{{cite journal | vauthors=((Björkenstam, C.)), ((Möller, J.)), ((Ringbäck, G.)), ((Salmi, P.)), ((Hallqvist, J.)), ((Ljung, R.)) | journal=PLoS ONE | title=An Association between Initiation of Selective Serotonin Reuptake Inhibitors and Suicide - A Nationwide Register-Based Case-Crossover Study | volume=8 | issue=9 | pages=e73973 | date=9 September 2013 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3767591/ | issn=1932-6203 | doi=10.1371/journal.pone.0073973}}</ref> - Upon first introduction, some users (especially people under the age of 25)<ref>{{Citation | title=What to know about antidepressants for kids and teens | url=https://www.mayoclinic.org/diseases-conditions/teen-depression/in-depth/antidepressants/art-20047502}}</ref> can experience increase suicidal and self harming thoughts and behaviors. This effect usually subsides within 6-8 weeks.
*'''[[Effect::Insomnia]]'''
*'''[[Effect::Insomnia]]'''
Line 74: Line 74:
*'''[[Effect::Irritability]]'''
*'''[[Effect::Irritability]]'''
*'''[[Effect::Motivation suppression]]'''
*'''[[Effect::Motivation suppression]]'''
*'''[[Effect::Headaches]]'''
*'''[[Effect::Headache]]'''
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Dream potentiation]]'''
}}
}}
Retrieved from "http://psy.st/wiki/Selective_serotonin_reuptake_inhibitor"